By Michael Quigley, Director of Research, LSN
Developing and commercializing a product in the life science space is notoriously capital intensive and usually involves a high level of risk. To assist with this difficult development process, many organizations have formed that are designing and utilizing new approaches to help move science forward in the early stages of development and clinical research. These include Studios, Incubators, Accelerators, and Funds that aim to create more financially efficient and de-risked models of engagement for companies and investors. The RESI conference will bring together some of the best and brightest of these groups to discuss how they are creating, coaching, and funding life science companies in a more productive manner.
During this panel, moderated by Dennis Ford, CEO & founder of Life Science Nation, the audience will hear from:
- Melinda Richter, Head, Johnson & Johnson Innovation, JLABS
- Bill McKeon, EVP, CSO, & COO, Texas Medical Center
- Lisa Rhoads, Managing Director, Easton Capital
- David Lucchino, Entrepreneur In Residence, Puretech
- Leo Linbeck, III, Chairman & Founder, Fannin Innovation Studio
Although the forming of virtual companies has shown great promise in reducing costs and keeping companies nimble, along the product development pathway, many inefficiencies remain. This panel will discuss what some of the most cutting-edge groups in the space are doing to tackle these challenges. Conference attendees are sure to gain insight from these individuals who are working to make the life science product development process more streamlined.
Next Phase Newsletter 
Leave a comment